{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-337646","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2025-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.652219+00:00","generated_at":"2026-05-16T11:55:03.736196+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioAtla enters $40M SPV deal to advance Oz-V Phase 3; retains 65% ownership","bullets":["Total $40M from Inversagen AI for 35% of SPV units; initial $5M closing by Jan 30, 2026.","BioAtla retains 65% ownership of Oz-V across all solid tumor indications after transaction.","Proceeds fund Phase 3 trial for Oz-V in 2L+ OPSCC; enrollment expected to begin early 2026.","Related-party transaction: Chairman/CEO Dr. Jay Short and spouse are managers of Inversagen entities."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-337646","json":"https://secwatch.observer/filing/0001193125-25-337646.json","markdown":"https://secwatch.observer/filing/0001193125-25-337646.md","text":"https://secwatch.observer/filing/0001193125-25-337646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/0001193125-25-337646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/d20340d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:55:03.736196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da3e6123dd8d6f12255962238e1d7635a113d0c6","claim":"BioAtla, Inc. entered into Investment Agreement with Inversagen AI, LLC and Alliance International Resources Corp. valued at aggregate $40 million (effective 2025-12-30).","evidence_excerpt":"On December 30, 2025, BioAtla, Inc. (“the Company” or “BioAtla”) entered into an Investment Agreement (the “Investment Agreement”) with Inversagen AI, LLC, a Delaware limited liability company (“Inversagen AI”), and Alliance International Resources Corp., a Nevada corporation (“AIRC”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/0001193125-25-337646-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Inversagen AI, LLC and Alliance International Resources Corp."},{"label":"Value","value":"aggregate $40 million"},{"label":"Effective","value":"2025-12-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}